Research & Literature

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.

Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al.

Haematologica 2015; (100(9)):1139-45 doi:10.3324/haematol.2014.119545.

Comprehensively understanding fatigue in patients with myeloproliferative neoplasms.

Scherber RM, Kosiorek HE, Senyak Z, et al.

Cancer 2016; (122(3)):477-85 doi:10.1002/cncr.29753.

Contemporary approach to essential thrombocythemia and polycythemia vera.

Aruch D, Mascarenhas J

Current opinion in hematology 2016; (23(2)):150-60 doi:10.1097/MOH.0000000000000216.

The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances.

Barbui T, Thiele J, Gisslinger H, et al.

Blood reviews 2016; (30(6)):453-459 doi:10.1016/j.blre.2016.06.001.

Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.

Shide K, Kameda T, Yamaji T, et al.

Leukemia 2017; (31(5)):1136-1144 doi:10.1038/leu.2016.308.

Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.

Tefferi A

American journal of hematology 2016; (91(12)):1262-1271 doi:10.1002/ajh.24592.

Update from the latest WHO classification of MPNs: a user's manual.

Passamonti F, Maffioli M

Hematology. American Society of Hematology. Education Program 2016; (2016(1)):534-542 doi:10.1182/asheducation-2016.1.534.

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Mesa R, Jamieson C, Bhatia R, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2016; (14(12)):1572-1611 doi:10.6004/jnccn.2016.0169.

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

Rumi E, Cazzola M

Blood 2017; (129(6)):680-692 doi:10.1182/blood-2016-10-695957.

Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.

Vainchenker W, Kralovics R

Blood 2017; (129(6)):667-679 doi:10.1182/blood-2016-10-695940.

Feasibility study of online yoga for symptom management in patients with myeloproliferative neoplasms.

Huberty J, Eckert R, Gowin K, et al.

Haematologica 2017; (102(10)):e384-e388 doi:10.3324/haematol.2017.168583.

A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.

Barbui T, Vannucchi AM, Finazzi G, et al.

American journal of hematology 2017; (92(11)):1131-1136 doi:10.1002/ajh.24851.

Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm.

Ghai S, Rai S

South Asian journal of cancer 2017; (6(2)):75-78 doi:10.4103/2278-330X.208854.

Genetic Risk Assessment in Myeloproliferative Neoplasms.

Tefferi A, Vannucchi AM

Mayo Clinic proceedings 2017; (92(8)):1283-1290 doi:10.1016/j.mayocp.2017.06.002.

MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients.

ElNahass YH, Mahmoud HK, Mattar MM, et al.

Leukemia & lymphoma 2018; (59(4)):844-854 doi:10.1080/10428194.2017.1365852.

Approach to MPN Symptom Assessment.

Geyer H, Mesa RA

Current hematologic malignancy reports 2017; (12(5)):381-388 doi:10.1007/s11899-017-0399-5.

Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.

Patterson-Fortin J, Moliterno AR

Current hematologic malignancy reports 2017; (12(5)):424-431 doi:10.1007/s11899-017-0411-0.

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.

Mesa RA, Jamieson C, Bhatia R, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2017; (15(10)):1193-1207.

CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.

Ojeda MJ, Bragós IM, Calvo KL, et al.

Hematology (Amsterdam, Netherlands) 2018; (23(4)):208-211 doi:10.1080/10245332.2017.1385891.

Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.

Misawa K, Yasuda H, Araki M, et al.

International journal of hematology 2018; (107(6)):673-680 doi:10.1007/s12185-018-2421-7.

Diagnosis and management of prefibrotic myelofibrosis.

Rumi E, Sant'Antonio E, Boveri E, et al.

Expert review of hematology 2018; (11(7)):537-545 doi:10.1080/17474086.2018.1484280.

Recurrent ischaemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasms.

Stefanou MI, Richter H, Härtig F, et al.

European journal of neurology 2019; (26(6)):903-e64 doi:10.1111/ene.13907.

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model.

Vallapureddy RR, Mudireddy M, Penna D, et al.

Blood cancer journal 2019; (9(2)):12 doi:10.1038/s41408-019-0175-y.

Thromboembolic events in polycythemia vera.

Griesshammer M, Kiladjian JJ, Besses C

Annals of hematology 2019; (98(5)):1071-1082 doi:10.1007/s00277-019-03625-x.

Targeting SOCS Proteins to Control JAK-STAT Signalling in Disease.

Durham GA, Williams JJL, Nasim MT, Palmer TM

Trends in pharmacological sciences 2019; (40(5)):298-308 doi:10.1016/j.tips.2019.03.001.

Long term follow-up after liver transplantation from a JAK2 mutation positive donor.

Lazo-Langner A, Ainsworth P, McAlister V

Hepatobiliary surgery and nutrition 2019; (8(2)):189-191 doi:10.21037/hbsn.2019.01.06.

Hematocrit levels and thrombotic events in patients with polycythemia vera: an analysis of Veterans Health Administration data.

Parasuraman S, Yu J, Paranagama D, et al.

Annals of hematology 2019; (98(11)):2533-2539 doi:10.1007/s00277-019-03793-w.

Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia.

Vu HA, Thao TT, Dong CV, et al.

Asian Pacific journal of cancer prevention : APJCP 2019; (20(9)):2775-2780 doi:10.31557/APJCP.2019.20.9.2775.

Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.

Tefferi A, Guglielmelli P, Lasho TL, et al.

British journal of haematology 2020; (189(2)):291-302 doi:10.1111/bjh.16380.

The new WHO classification for essential thrombocythemia calls for revision of available evidences.

Barbui T, Thiele J, Ferrari A, et al.

Blood cancer journal 2020; (10(2)):22 doi:10.1038/s41408-020-0290-9.

Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map.

Shallis RM, Wang R, Davidoff A, et al.

Blood reviews 2020; (42()):100706 doi:10.1016/j.blre.2020.100706.

Prognostic models in the myeloproliferative neoplasms.

Grinfeld J

Blood reviews 2020; (42()):100713 doi:10.1016/j.blre.2020.100713.

A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic.

How J, Hobbs GS

Journal of the National Comprehensive Cancer Network : JNCCN 2020; (18(9)):1271-1278.

Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition.

Padrnos L, Scherber R, Geyer H, et al.

Cancer medicine 2020; (9(22)):8301-8309 doi:10.1002/cam4.3380.

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.

Gerds AT, Savona MR, Scott BL, et al.

Blood advances 2020; (4(22)):5825-5835 doi:10.1182/bloodadvances.2020003314.

Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations.

Gangat N, Tefferi A

American journal of hematology 2021; (96(3)):354-366 doi:10.1002/ajh.26067.

Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression.

Bartels S, Vogtmann J, Schipper E, et al.

European journal of haematology 2021; (106(4)):520-528 doi:10.1111/ejh.13579.

Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.

Shallis RM, Zeidan AM, Wang R, Podoltsev NA

Hematology/oncology clinics of North America 2021; (35(2)):177-189 doi:10.1016/j.hoc.2020.11.005.

Accelerated and Blast Phase Myeloproliferative Neoplasms.

Jain T, Rampal RK

Hematology/oncology clinics of North America 2021; (35(2)):325-335 doi:10.1016/j.hoc.2020.12.008.

Polycythemia Vera (PV): Update on Emerging Treatment Options.

Benevolo G, Vassallo F, Urbino I, Giai V

Therapeutics and clinical risk management 2021; (17()):209-221 doi:10.2147/TCRM.S213020.

Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions.

Gong B, Li D, Kusko R, et al.

Genome biology 2021; (22(1)):109 doi:10.1186/s13059-021-02315-0.

Quantification of JAK2V617F mutation load by droplet digital PCR can aid in diagnosis of myeloproliferative neoplasms.

Zheng CF, Zhao XX, Chen XH, et al.

International journal of laboratory hematology 2021; (43(4)):645-650 doi:10.1111/ijlh.13560.

Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

Zeeh FC, Meyer SC

Hamostaseologie 2021; (41(3)):197-205 doi:10.1055/a-1447-6667.

Daily living and rehabilitation needs in patients and caregivers affected by myeloproliferative neoplasms (MPN): A qualitative study.

Rossau HK, Kjerholt M, Brochmann N, et al.

Journal of clinical nursing 2022; (31(7-8)):909-921 doi:10.1111/jocn.15944.

Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN).

Zulkeflee RH, Zulkafli Z, Johan MF, et al.

International journal of environmental research and public health 2021; (18(14)) doi:10.3390/ijerph18147582.

Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.

Sureau L, Orvain C, Ianotto JC, et al.

Blood cancer journal 2021; (11(7)):135 doi:10.1038/s41408-021-00526-z.

Myeloproliferative disorders: A retrospective cohort study.

Mhmed Ali R, Masoud V

Annals of medicine and surgery (2012) 2021; (68()):102628 doi:10.1016/j.amsu.2021.102628.

The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia.

Moser B, Edtmayer S, Witalisz-Siepracka A, Stoiber D

Biomedicines 2021; (9(8)) doi:10.3390/biomedicines9081051.

Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.

Verstovsek S, Yu J, Scherber RM, et al.

Leukemia & lymphoma 2022; (63(3)):694-702 doi:10.1080/10428194.2021.1992756.

Lab tests for MPN.

Moncada A, Pancrazzi A

International review of cell and molecular biology 2022; (366()):187-220 doi:10.1016/bs.ircmb.2021.02.010.

Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.

Pasca S, Chifotides HT, Verstovsek S, Bose P

International review of cell and molecular biology 2022; (366()):83-124 doi:10.1016/bs.ircmb.2021.02.008.

Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.

Edahiro Y, Ohishi K, Gotoh A, et al.

International journal of hematology 2022; (116(2)):215-227 doi:10.1007/s12185-022-03341-9.

Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.

Htun HL, Lian W, Wong J, et al.

Cancer epidemiology 2022; (79()):102175 doi:10.1016/j.canep.2022.102175.

Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia.

Abdelghani M, Hammami H, Zidi W, et al.

Journal of clinical laboratory analysis 2022; (36(8)):e24522 doi:10.1002/jcla.24522.

Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study.

Christensen SF, Svingel LS, Kjaersgaard A, et al.

European journal of haematology 2022; (109(5)):526-541 doi:10.1111/ejh.13841.

Hematocrit, White Blood Cells, and Thrombotic Events in the Veteran Population With Polycythemia Vera.

Tashi T

Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2022; (39(Suppl 2)):S43-S46 doi:10.12788/fp.0243.

Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.

Mora B, Passamonti F

Current hematologic malignancy reports 2022; (17(5)):127-139 doi:10.1007/s11899-022-00672-6.

The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms.

Thiele J, Kvasnicka HM, Orazi A, et al.

American journal of hematology 2023; (98(1)):166-179 doi:10.1002/ajh.26751.

Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms.

Kalmer M, Pannen K, Lemanzyk R, et al.

Annals of hematology 2022; (101(12)):2655-2663 doi:10.1007/s00277-022-05000-9.

A Case Report on Hepatic Extramedullary Hematopoiesis as the Manifestation of Progression to Secondary Myelofibrosis in a Patient with Essential Thrombocytopenia.

McArthur KI, Papayanis PN, Nguyen MHK, et al.

Hematology reports 2022; (14(4)):286-289 doi:10.3390/hematolrep14040040.

JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.

Stein BL

Leukemia & lymphoma 2023; (64(2)):292-299 doi:10.1080/10428194.2022.2136970.

Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm.

Abbou N, Piazzola P, Gabert J, et al.

Cells 2022; (12(1)) doi:10.3390/cells12010105.

Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan.

Kuo MC, Chuang WY, Chang H, et al.

American journal of clinical pathology 2023; (159(5)):474-483 doi:10.1093/ajcp/aqac173.

Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives.

Barosi G, Rosti V, Gale RP

Leukemia 2023; (37(4)):725-727 doi:10.1038/s41375-023-01861-9.

Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration.

Jain T, Tsai HL, Elmariah H, et al.

Haematologica 2023; (108(12)):3321-3332 doi:10.3324/haematol.2023.283426.

Jaktinib and momelotinib for the treatment of myelofibrosis-Birds of a feather?

Tefferi A

American journal of hematology 2023; (98(10)):1517-1519 doi:10.1002/ajh.27036.

Easily Applicable Predictive Score for Differential Diagnosis of Prefibrotic Primary Myelofibrosis from Essential Thrombocythemia.

Lekovic D, Bogdanovic A, Sobas M, et al.

Cancers 2023; (15(16)) doi:10.3390/cancers15164180.

Change in Polycythemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials

Gisslinger H

Turkish journal of haematology : official journal of Turkish Society of Haematology 2023; (40(4)):266-268 doi:10.4274/tjh.galenos.2023.2023.0419.

Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.

Verma T, Papadantonakis N, Peker Barclift D, Zhang L

Cancers 2024; (16(3)) doi:10.3390/cancers16030514.

SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis.

Vachhani P, Loghavi S, Bose P

Clinical lymphoma, myeloma & leukemia 2024; (24(7)):413-426 doi:10.1016/j.clml.2024.01.009.

Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.

Gupta V, Oh S, Devos T, et al.

Leukemia & lymphoma 2024; (65(7)):965-977 doi:10.1080/10428194.2024.2328800.

Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms with Relation to Genetic Burden and Thrombosis

Ümit EG, Baysal M, Kırkızlar HO, Demir AM

Turkish journal of haematology : official journal of Turkish Society of Haematology 2024; (41(3)):175-181 doi:10.4274/tjh.galenos.2024.2024.0011.

Translation, Cultural Adaptation, and Validation into Romanian of the Myeloproliferative Neoplasm Symptom Assessment Form-Total Symptom Score (MPN-SAF TSS or MPN-10) Questionnaire.

Găman MA, Scherber RM, Ursuleac I, et al.

Journal of clinical medicine 2024; (13(11)) doi:10.3390/jcm13113284.

Association between JAK2V617F variable allele frequency and risk of thrombotic events in patients with myeloproliferative neoplasms.

Brown R, Jasiakiewicz J, Greer V, et al.

Irish journal of medical science 2024; (193(6)):2883-2888 doi:10.1007/s11845-024-03776-5.

Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.

Harrison CN, Mesa R, Talpaz M, et al.

The Lancet. Haematology 2024; (11(10)):e729-e740 doi:10.1016/S2352-3026(24)00212-6.

Pathogenesis and management of high molecular risk myeloproliferative neoplasms.

Ling VY, Heidel FH, Bywater MJ

Haematologica 2025; (110(4)):863-876 doi:10.3324/haematol.2023.283987.

Molecular profiling in MPN: who should have it and why?

Chee A, Mead AJ

Hematology. American Society of Hematology. Education Program 2024; (2024(1)):524-534 doi:10.1182/hematology.2024000576.

How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024.

Griesshammer M, Al-Ali HK, Eckardt JN, et al.

Annals of hematology 2025; (104(1)):295-306 doi:10.1007/s00277-025-06191-7.

A case report of donor cell-derived hematologic neoplasms 9 years after allogeneic hematopoietic cell transplantation.

Mroczkowska-Bękarciak A, Wróbel T

Oncotarget 2025; (16()):44-50 doi:10.18632/oncotarget.28686.

Evolution of WHO diagnostic criteria in "Classical Myeloproliferative Neoplasms" compared with the International Consensus Classification.

Thiele J, Kvasnicka HM, Gianelli U, et al.

Blood cancer journal 2025; (15(1)):31 doi:10.1038/s41408-025-01235-7.

Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib.

Butler LA, Forsyth C, Harrison C, Perkins AC

EJHaem 2025; (6(2)):e70007 doi:10.1002/jha2.70007.

Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms.

Yu D, Zhang H, Song Y, et al.

Haematologica 2025; (110(11)) doi:10.3324/haematol.2024.286123.

Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fraction.

Sisoudiya SD, Tukachinsky H, Keller-Evans RB, et al.

NPJ precision oncology 2025; (9(1)):190 doi:10.1038/s41698-025-00991-w.

[Efficacy of ruxolitinib and prognostic factors in patients with myelofibrosis stratified by age].

Liu XH, Yu Y, Yan FM, et al.

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2025; (46(8)):722-730 doi:10.3760/cma.j.cn121090-20250113-00025.

From symptom scales to regulatory endpoints: the evolution and clinical impact of patient-reported outcome measures in myeloproliferative neoplasms.

Chen M, Zheng C, Xie J, et al.

Clinical and experimental medicine 2025; (25(1)):330 doi:10.1007/s10238-025-01830-9.

Risk and Outcomes of Second Malignancies in Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasm: A SEER Database Analysis.

Mishra R, Bagga A, Sharafeldin N, et al.

JCO oncology practice 2025; OP2500431 doi:10.1200/OP-25-00431.

Polycythemia Vera and Essential Thrombocythemia: A Nationwide Population-Based Study on Treatment Patterns, Vascular Complications and Survival.

Larsson AE, Renlund H, Andréasson B, et al.

European journal of haematology 2026; (116(5)):545-557 doi:10.1111/ejh.70113.

Risk of Transformation to Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients With Myeloproliferative Neoplasms Over Attained Age and Time Since Diagnosis: A Nationwide Cohort Study.

Batyrbekova N, Landtblom AR, Hultcrantz M, et al.

European journal of haematology 2026; (116(6)):850-862 doi:10.1111/ejh.70141.